Autodesk Inc vs Eli Lilly And Co — how do they compare? Autodesk Inc trades at $247.35 (market cap $53.12B), while Eli Lilly And Co trades at $1,216.3 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 20.3× Autodesk Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Autodesk Inc pays none. Which is the better fit depends on your goals.
| ADSK | LLY | |
|---|---|---|
Market Cap | $53.12B | $1.08T |
Sector | Technology | Health |
52-Week High | $326.79 | $1.24K |
52-Week Low | $187.72 | $639.43 |
Enterprise Value | $52.92B | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $247.39, down 3.39% in the latest session, but maintains strong fundamentals with consistent earnings beats and robust revenue growth. The stock shows a bullish technical trend with moving averages supporting upside momentum, while RSI levels indicate potential overbought conditions. Recent financial performance demonstrates expanding profit margins and healthy cash flow generation, supported by the company's dominant position in design software markets.
The outlook remains positive with analyst consensus favoring continued growth, though elevated valuation multiples and competitive pressures present risks. Upside potential exists toward the $302.23 consensus price target, supported by strong institutional backing and strategic AI investments. Key risks include market volatility and execution challenges in maintaining premium valuation levels.
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Trailing returns across standard periods
Latest headlines on both assets
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →